Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
_256_384.jpg)
As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
Self-collection devices designed for ease of use and safety
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
Subscribe To Our Newsletter & Stay Updated
